HC Wainwright Has Negative Outlook for KTTA FY2026 Earnings

Pasithea Therapeutics Corp. (NASDAQ:KTTA) – Analysts at HC Wainwright cut their FY2026 EPS estimates for Pasithea Therapeutics in a research report issued on Tuesday, March 31st. HC Wainwright analyst S. Nik now forecasts that the company will earn ($1.86) per share for the year, down from their previous forecast of ($0.68). HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. HC Wainwright also issued estimates for Pasithea Therapeutics’ FY2027 earnings at ($2.10) EPS and FY2028 earnings at ($2.30) EPS.

Other equities research analysts have also recently issued research reports about the stock. Zacks Research raised shares of Pasithea Therapeutics to a “hold” rating in a report on Tuesday, December 9th. Wall Street Zen upgraded Pasithea Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, January 18th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Pasithea Therapeutics in a research note on Friday, March 27th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $3.00.

Pasithea Therapeutics Trading Up 3.5%

KTTA opened at $0.77 on Friday. Pasithea Therapeutics has a 12 month low of $0.28 and a 12 month high of $3.79. The company has a market cap of $19.20 million, a PE ratio of -0.22 and a beta of 0.25. The company has a 50 day moving average of $0.80 and a 200 day moving average of $0.85.

Pasithea Therapeutics (NASDAQ:KTTA) last posted its earnings results on Monday, March 30th. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.71).

Institutional Trading of Pasithea Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC lifted its holdings in Pasithea Therapeutics by 43.7% in the third quarter. Citadel Advisors LLC now owns 67,341 shares of the company’s stock worth $48,000 after buying an additional 20,483 shares during the period. Geode Capital Management LLC raised its position in shares of Pasithea Therapeutics by 113.9% in the 4th quarter. Geode Capital Management LLC now owns 54,495 shares of the company’s stock worth $70,000 after acquiring an additional 29,020 shares in the last quarter. Jane Street Group LLC raised its position in shares of Pasithea Therapeutics by 137.0% in the 4th quarter. Jane Street Group LLC now owns 59,372 shares of the company’s stock worth $77,000 after acquiring an additional 34,319 shares in the last quarter. Two Sigma Investments LP purchased a new position in shares of Pasithea Therapeutics in the 3rd quarter valued at approximately $26,000. Finally, AdvisorShares Investments LLC boosted its position in shares of Pasithea Therapeutics by 18.2% during the fourth quarter. AdvisorShares Investments LLC now owns 304,721 shares of the company’s stock valued at $393,000 after purchasing an additional 47,025 shares in the last quarter. Institutional investors own 23.92% of the company’s stock.

About Pasithea Therapeutics

Pasithea Therapeutics, Inc (NASDAQ: KTTA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and eventual commercialization of engineered antibody therapeutics for immunological diseases. Leveraging a proprietary discovery engine that integrates advanced computational biology, high-throughput screening and structural analysis, the company aims to identify and generate novel therapeutic molecules that modulate key immune pathways.

The company’s pipeline consists of multiple preclinical and early clinical candidates targeting autoimmune and inflammatory disorders.